PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: VLI Research, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Third Annual Ubiquitin Drug Discovery & Diagnostics Conference to be Held in Philadelphia, PA - The third annual Ubiquitin Drug Discovery & Diagnostics conference will be held in Philadelphia from July 11th to 13th, 2011 and will bring together ubiquitin experts from academia and industry - UbiquitinConference.com
Third Annual Ubiquitin Drug Discovery & Diagnostics Conference to be Held in Philadelphia, PA

 

NewswireToday - /newswire/ - Philadelphia, PA, United States, 2010/12/22 - The third annual Ubiquitin Drug Discovery & Diagnostics conference will be held in Philadelphia from July 11th to 13th, 2011 and will bring together ubiquitin experts from academia and industry - UbiquitinConference.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The upcoming 2011 Ubiquitin Drug Discovery & Diagnostics Conference, to be held next year in Philadelphia from July 11th to the 13th, marks the third-annual landmark gathering of ubiquitin-focused professionals from academia and industry.

Building on the success of the 2009 and 2010 events, this premier conference in ubiquitin research and its application to the treatment of human disease host an international gathering of academic, industry and government professionals.

The three-day conference and workshop is unique in its focus on drug discovery within the ubiquitin pathway, and in its balance of both industry and academic interests. Delegates will have the opportunity to participate in a series of roundtable discussions and poster sessions, and to network with like-minded researchers from around the world.

The program will begin with an innovative pre-conference workshop covering various topics in assays and assay platforms, substrate identification, and ubiquitylation. The focus will be on technical advances in ubiquitin research and its application to the treatment of human disease.

Keynote speakers for the main conference include Millennium Pharmaceuticals' Chief Scientific Officer Joseph Bolen and.Keith Wilkinson, Professor of Biochemistry at Emory University. The conference program will cover topics in oncology, infectious diseases, neurodegeneration, inflammation, diabetes, and muscle wasting.

Those interested in attending the conference should register as soon as possible to secure their attendance and accommodation – discounted rates at the Four Seasons Hotel are available for delegates on a first-come, first-serve basis.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: VLI Research, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Third Annual Ubiquitin Drug Discovery & Diagnostics Conference to be Held in Philadelphia, PA

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sarah Riedel - VLI-Research.com 
610-644-0585 x319 info[.]ubiquitinconference.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any VLI Research, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From VLI Research, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)